Bayer: Leiomyoma trials

The registry lists 12 Leiomyoma studies with Bayer as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 2Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)TerminatedNCT03400956Phase 3Results posted
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)TerminatedNCT03400943Phase 3Results posted
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine FibroidsTerminatedNCT03194646Phase 3Results posted
• Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, JapCompletedNCT02131662Phase 2Results posted
• Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine FibroidsWithdrawnNCT03699176Phase 3
• A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual BleedingTerminatedNCT03476928Phase 3
• Pharmacokinetics and Safety of Vilaprisan in Renal ImpairmentCompletedNCT03411980Phase 1
• Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is PlannedTerminatedNCT03342859Phase 1
• A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine FibroidsTerminatedNCT03240523Phase 3
• Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)CompletedNCT03092999Phase 1
• Assess Safety and Efficacy of Vilaprisan in Patients With Uterine FibroidsCompletedNCT02465814Phase 2
• Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670CompletedNCT01816815Phase 1